AngioDynamics, Inc. (ANGO) Tops Q4 EPS by 1c; Guides In-Line
Tweet
Share
E-mailGet Alerts ANGO Hot Sheet
Price: $5.92 -1.82%
Revenue Growth %: -18.2%
Financial Fact:
Amortization of intangibles: 4.24M
Today's EPS Names:
CP, RUSHA, SEIC, More
Revenue Growth %: -18.2%
Financial Fact:
Amortization of intangibles: 4.24M
Today's EPS Names:
CP, RUSHA, SEIC, More
Join SI Premium – FREE
AngioDynamics, Inc. (NASDAQ: ANGO) reported Q4 EPS of $0.07, $0.01 better than the analyst estimate of $0.06. Revenue for the quarter came in at $90 million versus the consensus estimate of $86.43 million.
AngioDynamics, Inc. sees FY2013 EPS of $0.31-0.35, versus the consensus of $0.33. AngioDynamics, Inc. sees FY2013 revenue of $346-352 million, versus the consensus of $350.33 million.
AngioDynamics, Inc. sees Q1 2013 EPS of $0.10-0.12, versus the consensus of $0.08. AngioDynamics, Inc. sees Q1 2013 revenue of $81-84 million, versus the consensus of $84.74 million.
"The fourth quarter was highlighted by encouraging signs of progress, and while the Vascular Access franchise continues to face challenges despite the strong performance of our BioFlo technology, the Peripheral Vascular, Oncology/Surgery and International franchises all experienced healthy improvements over the fiscal 2013 third quarter," said Joseph M. DeVivo, President and Chief Executive Officer. "We saw excellent early data on our BioFlo PICCs, which now represent 20% of AngioDynamics' worldwide PICC revenue; exceeded our AngioVac system forecast with $1 million in sales in the fourth quarter alone; and received FDA approval for our NanoKnife system Prostate IDE. Our Oncology/Surgery franchise was further bolstered by a 25% increase in worldwide thermal ablation revenue compared to the fiscal 2013 third quarter. Coupled with returned stability in our sales forces, we believe these key drivers will return AngioDynamics to growth in FY 2014."
For earnings history and earnings-related data on AngioDynamics, Inc. (ANGO) click here.
AngioDynamics, Inc. sees FY2013 EPS of $0.31-0.35, versus the consensus of $0.33. AngioDynamics, Inc. sees FY2013 revenue of $346-352 million, versus the consensus of $350.33 million.
AngioDynamics, Inc. sees Q1 2013 EPS of $0.10-0.12, versus the consensus of $0.08. AngioDynamics, Inc. sees Q1 2013 revenue of $81-84 million, versus the consensus of $84.74 million.
"The fourth quarter was highlighted by encouraging signs of progress, and while the Vascular Access franchise continues to face challenges despite the strong performance of our BioFlo technology, the Peripheral Vascular, Oncology/Surgery and International franchises all experienced healthy improvements over the fiscal 2013 third quarter," said Joseph M. DeVivo, President and Chief Executive Officer. "We saw excellent early data on our BioFlo PICCs, which now represent 20% of AngioDynamics' worldwide PICC revenue; exceeded our AngioVac system forecast with $1 million in sales in the fourth quarter alone; and received FDA approval for our NanoKnife system Prostate IDE. Our Oncology/Surgery franchise was further bolstered by a 25% increase in worldwide thermal ablation revenue compared to the fiscal 2013 third quarter. Coupled with returned stability in our sales forces, we believe these key drivers will return AngioDynamics to growth in FY 2014."
For earnings history and earnings-related data on AngioDynamics, Inc. (ANGO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) tops earnings expectations but revenue falls short
- Simmons First National Corp (SFNC) Misses Q1 EPS by 1c
- Farmers National Banc (FMNB) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
